Table 1

Data extraction form for primary studies

Study ID
Title
Author
Country of study conductUSA
UK
Canada
Australia
Other
Study characteristics
Aim
DesignRandomised controlled trial
Non-randomised experimental study
Cohort study
Cross-sectional study
Case–control study
Case series
Case report
Other
Start date
End date
Funding source
Conflict of interest
Participant characteristics
Population description
Inclusion criteria
Exclusion criteria
Sample size (n)
Birth weight (grams)
Gestational age (weeks)
Postnatal age (weeks)
Underlying condition
Comorbidities
Concurrent medications
Intervention/exposure details
AVP or terlipressin dosing (mg/kg/dose)
AVP or terlipressin treatment duration (days)
AVP or terlipressin route of administration
Control details
PharmacotherapyDopamine
Dobutamine
Epinephrine
Norepinephrine
Placebo
Other
Outcomes
Primary outcomes
Improvement in end organ perfusion details
  • SBP

  • DBP

  • MBP

  • Urine output

  • Inotropic support

  • Serum lactate

Mortality
  • Death before discharge

Secondary outcomes*
Major neurosensory disabilityNeurosensory disability
  • Moderate to severe motor or cognitive impairment

  • Severe visual or hearing impairment

Occurrence of adverse eventsAdverse events
  • Peripheral tissue ischaemia

  • Gastrointestinal events

  • Renal events

  • Hepatic events

  • Hyponatraemia

  • *The secondary outcomes will be defined as reported in the primary studies.

  • AVP, arginine vasopressin; DBP, diastolic blood pressure; MBP, mean blood pressure; SBP, systolic blood pressure.